er though their third generation liver centric LNP. TKM-PLK1 is currently in phase II trial and is targeting three different forms of cancer, while TKM-Ebola specialises in the Zaire species of Ebola virus. The Company has two areas of particular interest in its future research; glycogen storage diseases